Tocainide is an orally active class 1b antiarrhythmic agent that interferes with cardiac sodium channels and typically used to treat ventricular arrhythmias. An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels.
- Mechanism
- Curator reviewed
Tocainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. Tocainide binds preferentially to the inactive state of the sodium channels.The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers.
- Primary indication
- For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.Curator reviewed
- Formula / weight
- C11H16N2O · 192.2575 g/mol (avg)
- First approval
- Canada, 2000
- Code names
- W-36095
Resolves to
BUJAGSGYPOAWEI-UHFFFAOYSA-NSMILESCC(N)C(=O)NC1=C(C)C=CC=C1CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Tocainide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account